- Lilly's EBGLYSS (lebrikizumab‑lbkz), an IL‑13 inhibitor, was dosed 250 mg every four weeks (Q4W) in the ADlong open‑label extension.
- Up to four years' continuous treatment showed observed outcomes: EASI‑75 94%, EASI‑90 75%, IGA 0/1 68%, Pruritus NRS ≤4 78%, and 80% achieved results without topical corticosteroids.
- Safety through year one aligned with the known profile; treatment‑related events included conjunctivitis (6.9%) and injection‑site reactions (0.6%).
- First‑year ADlong interim findings were presented at the AAD Annual Meeting, March 27–31, 2026 (Denver).
Study design
The ADlong Phase 3b open‑label extension evaluated lebrikizumab‑lbkz (EBGLYSS) 250 mg every four weeks as monthly maintenance in patients with moderate‑to‑severe atopic dermatitis, with interim first‑year findings presented at AAD 2026.
Efficacy
Observed results up to four years of continuous treatment: EASI‑75 94%, EASI‑90 75%, IGA 0/1 68%, Pruritus NRS ≤4 78%; 77% of patients received EBGLYSS monotherapy and 80% achieved outcomes without topical corticosteroids, with monthly maintenance dosing.
Safety
Safety through year one was consistent with the known profile and showed no new signals; most adverse events were mild or moderate and did not lead to discontinuation; reported treatment‑related events included conjunctivitis (6.9%) and injection‑site reactions (0.6%).
Additional findings
A post‑hoc analysis on EASI‑75 stable responders indicated fewer than one flare per patient per year with monthly EBGLYSS monotherapy; the ADlong study is ongoing for further follow‑up.
Mechanism
EBGLYSS is a monoclonal antibody that selectively binds IL‑13 with high affinity and slow dissociation, overlapping the IL‑4Rα binding site to prevent formation of the IL‑13 receptor complex and inhibit IL‑13 signaling, a driver of type‑2 skin inflammation.
